By Benjamin Horney ( August 20, 2014, 6:49 PM EDT) -- Generic-drug producer Mylan Inc., undisclosed Indian drugmakers, and private equity firms TPG Capital LLP, Advent International, KKR & Co. LP and Warburg Pincus LLC have made it to the second round of bidding for a mature drug portfolio being offered by GlaxoSmithKline PLC, The Wall Street Journal reported Wednesday. GSK's portfolio includes prescription medicine brands — such as the antidepressant drug Paxil and the hepatitis B drug Zeffix — that have annual sales of about $1.66 billion, according to WSJ. The sale price could end up being worth more than $3 billion, the report said....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.